

NextCell and FUJIFILM Biosciences Launch New Commercial Platform Comprised of RUO Stromal Cells and Cell Culture Media

NextCell Pharma AB ("NextCell" or "the Company") today announces that in collaboration with FUJIFILM Biosciences, NextCell-Cord RUO cells have been commercially launched.

NextCell's specialism in cell therapy using umbilical cord mesenchymal stromal cells (MSC) and FUJIFILM Biosciences, a global leader in the life science market, today announced the global commercial launch from their strategic collaboration. The offering consists of FUJIFILM Biosciences PRIME-XV MSC Expansion XFSM medium and NextCell's first commercial product, NextCell-Cord RUO, a research-use-only (RUO) MSC product derived from umbilical cord tissue.

Some of the challenges faced in MSC research are heterogeneity of MSCs, immunocompatibility, and inefficient manufacturing. NextCell-Cord RUO provides researchers a more consistent, efficient, and accessible source of cells. The collaboration with FUJIFILM Biosciences to provide these cells with media delivers a high-quality, standardised solution for researchers working in immunology, regenerative medicine, and cell therapy development.

NextCell-Cord RUO is available across all major global markets through FUJIFILM Biosciences as a standalone product or bundled with Fujifilm's PRIME-XV MSC Expansion XFSM media, recombinant growth factors and reagents.

*"FUJIFILM Biosciences is committed to paving a better way forward with life science products, services, and solutions that serve the evolving needs of our academia, biotech, and pharmaceutical partners worldwide," said **Brandon Pence, President and Chief Operations Officer at FUJIFILM Biosciences.** "Our strategic alliance with NextCell Pharma further strengthens our commitment to enabling our customers to achieve more with products and solutions they need every day to help create a healthier world for all."*

*"This product launch is a milestone for NextCell Pharma AB," said **Mathias Svahn, Chief Executive Officer of NextCell Pharma.** "It brings our proprietary MSC platform to a global audience, and we are proud to do so in close collaboration with FUJIFILM Biosciences, a trusted leader in life science solutions."*

*"We've worked with FUJIFILM Biosciences to ensure that this product meets the needs of researchers and drug developers who value consistency, scalability and translational relevance," said **Dr Lindsay Davies, Chief Scientific Officer at NextCell Pharma.** "NextCell-Cord RUO reflects not only our clinical manufacturing expertise, but also a commitment to delivering high-quality, standardised MSC products that are scientifically robust and immediately usable in research and development workflows."*

NextCell-Cord RUO is available from FUJIFILM Biosciences or direct from NextCell.

The impact on NextCell's operating result and earnings per share is assessed to be limited for the upcoming 12-month period.

This press release has been prepared in consultation with FUJIFILM Biosciences, which means that certain technical terms have been used to reflect the international collaboration.

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO
Eric Gustafsson, CFO
Phone: 08-735 5595
E-mail: info@nextcellpharma.com

Websites:

NextCell Pharma AB: www.nextcellpharma.com

Cellaviva Sverige: www.cellaviva.se

Cellaviva Danmark: www.cellaviva.dk

QVance AB: www.qvance.se

LinkedIn: <https://www.linkedin.com/company/15255207/>

Twitter: <https://twitter.com/NextCellPharma>

Certified Adviser

The company's shares are listed on the Nasdaq First North Growth Market.

RedEye Nordic Growth AB is assigned as Certified Adviser.

About NextCell Pharma

NextCell Pharma is a clinical-stage cell therapy company developing ProTrans, a patent-protected platform based on allogeneic mesenchymal stromal cells (MSCs) from umbilical cord tissue. Using a proprietary selection algorithm, ProTrans delivers optimised cell tailored to specific indications. In type 1 diabetes, a single infusion has been shown to preserve insulin production and delay disease progression for at least five years. A Phase III trial is planned to commence upon securing a commercial partner. ProTrans is also being evaluated for other autoimmune and inflammatory conditions. NextCell's subsidiaries include Cellaviva, Scandinavia's largest private stem cell bank, and QVance, the Nordic region's first dedicated provider of quality services for developers of advanced therapies.

About FUJIFILM Biosciences

With a foundation in cell culture that dates back to 1970, FUJIFILM Biosciences is a global, full spectrum supplier to the life sciences market, providing products and services that assist customers in advancing healthcare initiatives. With an expanding portfolio of applications supported that include life science and

discovery research, cell and gene therapy, as well as the large-scale production of biotherapeutics and vaccines, the Company is trusted by researchers and manufacturers worldwide. For over 50 years, FUJIFILM Biosciences' Mission has been to enable life changing therapies and vaccines for a healthier world. The Company's facilities adhere to both ISO and FDA regulations, with manufacturing facilities that follow cGMP guidelines in the USA, Japan, and the Netherlands, and a media optimization center in China. All sites prioritize strategies that adhere to the FUJIFILM Sustainability Value Plan 2030 for sustainable growth. FUJIFILM Biosciences operates as a subsidiary of FUJIFILM Holdings America Corporation under FUJIFILM Holdings Corporation.

For more information, please visit: fujifilmbiosciences.fujifilm.com

FUJIFILM Holdings Corporation

FUJIFILM Holdings Corporation, headquartered in Tokyo, leverages its depth of knowledge and proprietary core technologies to deliver innovative products and services across the globe through the four key business segments of healthcare, electronics, business innovation, and imaging with over 70,000 employees. Guided and united by our Group Purpose of "giving our world more smiles," we address social challenges and create a positive impact on society through our products, services, and business operations. Under its medium-term management plan, VISION2030, which ends in FY2030, we aspire to continue our evolution into a company that creates value and smiles for various stakeholders as a collection of global leading businesses and achieve a global revenue of 4 trillion yen (29 billion USD at an exchange rate of 140 JPY/USD). For more information, please visit: www.fujifilmholdings.com.

For further details about our commitment to sustainability and Fujifilm's Sustainable Value Plan 2030, [click here](#).

FUJIFILM Media contacts

Lori Serles
FUJIFILM Biosciences
Phone: (949) 261-7800 x145
Email: lori.serles@fujifilm.com

Lily Jeffery
Zyme Communications
Phone: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com

To opt-out from receiving press releases from Zyme Communications, please email info@zymecommunications.com. To view our privacy policy, please [click here](#).